论文信息 - S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial - 字舞流文

S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial

C. Ishioka | H. Shimodaira | S. Morita | Y. Miyamoto | I. Iwanaga | Y. Komatsu | Y. Yamada | T. Denda | M. Gamoh | M. Tsuda | A. Sato | S. Yuki | S. Takahashi | H. Ohori | Shin Takahashi | M. Kotake | K. Kobayashi | M. Nakamura | T. Yamaguchi | Y. Kobayashi | K. Shimada | K. Kobayashi | Masafumi Nakamura | Sojiro Morita | H. Shimodaira | Yoshito Komatsu | C. Ishioka | Yuki Yamada | Takuhiro Yamaguchi | Yuji Miyamoto | Masanori Kotake | Ken Shimada | Atsushi Sato